The Experts below are selected from a list of 27078 Experts worldwide ranked by ideXlab platform

Janina Lulek - One of the best experts on this subject based on the ideXlab platform.

  • Cilostazol-loaded electrospun three-dimensional systems for potential Cardiovascular Application: Effect of fibers hydrophilization on drug release, and cytocompatibility
    Journal of colloid and interface science, 2018
    Co-Authors: Marek Rychter, Bartłomiej Milanowski, Marcin Jarek, Anna Baranowska-korczyc, Bartosz F. Grześkowiak, Mateusz Kempiński, Emerson Coy, Sławomir Borysiak, Janina Lulek
    Abstract:

    Abstract Currently marketed drug-eluting stents are non-selective in their anti-restenotic action. New active substance introduction to polymeric stents and vascular grafts can promote early re-endothelialization, crucial in preventing implant restenosis. Additionally, managing material hydrophobicity by blending synthetic polymers limits adverse effects on bulk properties and controls active substance release. However, the influence of hydrophilic synthetic polymer on human cells in the Cardiovascular system remains to be determined. In this report, effects of both poly(e-caprolactone) (PCL) fibers hydrophilization with Pluronic P123 (P123) and cilostazol (CIL) loading were studied. Physicochemical and mechanical properties of electrospun tubular structures produced from PCL and PCL/P123 fibers with and without CIL were investigated and compared. Release profiles studies and in vitro cell proliferation assays of electrospun materials were conducted. It was found that P123 located near the surface of electrospun fibers increased the rate of CIL release. PCL formulation sustained human umbilical vein endothelial cells (HUVEC) growth for 48 h. Despite improved hydrophilicity, PCL/P123 formulations were found to reduce HUVEC viability. Both PCL and PCL/P123 materials reduced primary aortic smooth muscle cells (PASM) viability after 48 h. In PCL formulations containing CIL, drug release caused a decrease in PASM viability. P123 blending with PCL was found to be as a useful pre-fabrication technique for modulating surface hydrophobicity of electrospun materials and the release profile of incorporated active substance. The cytotoxicity of P123 was evaluated to improve the design of drug-loaded vascular grafts for Cardiovascular Applications.

  • Cilostazol-Loaded Poly(ε-Caprolactone) Electrospun Drug Delivery System for Cardiovascular Applications
    Pharmaceutical Research, 2018
    Co-Authors: Marek Rychter, Bartłomiej Milanowski, Marcin Jarek, Barbara M. Maciejewska, Anna Baranowska-korczyc, Janina Lulek
    Abstract:

    Purpose The study discusses the value of electrospun cilostazol-loaded (CIL) polymer structures for potential vascular implant Applications. Methods Biodegradable polycaprolactone (PCL) fibers were produced by electrospinning on a rotating drum collector. Three different concentrations of CIL: 6.25%, 12.50% and 18.75% based on the amount of polymer, were incorporated into the fibers. The fibers were characterized by their size, shape and orientation. Materials characterization was carried out by Fourier Transformed Infrared spectroscopy (FTIR), Raman spectroscopy, differential scanning calorimetry (DSC) and X-ray diffraction (XRD). In vitro drug release study was conducted using flow-through cell apparatus (USP 4). Results Three-dimensional structures characterized by fibers diameter ranging from 0.81 to 2.48 μm were in the range required for Cardiovascular Application. DSC and XRD confirmed the presence of CIL in the electrospun fibers. FTIR and Raman spectra confirmed CIL polymorphic form. Elastic modulus values for PCL and the CIL-loaded PCL fibers were in the range from 0.6 to 1.1 GPa. The in vitro release studies were conducted and revealed drug dissolution in combination with diffusion and polymer relaxation as mechanisms for CIL release from the polymer matrix. Conclusions The release profile of CIL and nanomechanical properties of all formulations of PCL fibers demonstrate that the cilostazol loaded PCL fibers are an efficient delivery system for vascular implant Application.

Qiang Zhao - One of the best experts on this subject based on the ideXlab platform.

  • Ultrasound and Magnetic Responsive Drug Delivery Systems for Cardiovascular Application.
    Journal of cardiovascular pharmacology, 2020
    Co-Authors: Bei Qian, Qiang Zhao
    Abstract:

    With the increasing insight into molecular mechanisms of Cardiovascular disease, a promising solution involves directly delivering genes, cells, and chemicals to the infarcted myocardium or impaired endothelium. However, the limited delivery efficiency after administration fails to reach the therapeutic dose and the adverse off-target effect even causes serious safety concerns. Controlled drug release via external stimuli seems to be a promising method to overcome the drawbacks of conventional drug delivery systems (DDSs). Microbubbles and magnetic nanoparticles responding to ultrasound and magnetic fields respectively have been developed as an important component of novel DDSs. In particular, several attempts have also been made for the design and fabrication of dual-responsive DDS. This review presents the recent advances in the ultrasound and magnetic fields responsive DDSs in Cardiovascular Application, followed by their current problems and future reformation.

Marek Rychter - One of the best experts on this subject based on the ideXlab platform.

  • Cilostazol-loaded electrospun three-dimensional systems for potential Cardiovascular Application: Effect of fibers hydrophilization on drug release, and cytocompatibility
    Journal of colloid and interface science, 2018
    Co-Authors: Marek Rychter, Bartłomiej Milanowski, Marcin Jarek, Anna Baranowska-korczyc, Bartosz F. Grześkowiak, Mateusz Kempiński, Emerson Coy, Sławomir Borysiak, Janina Lulek
    Abstract:

    Abstract Currently marketed drug-eluting stents are non-selective in their anti-restenotic action. New active substance introduction to polymeric stents and vascular grafts can promote early re-endothelialization, crucial in preventing implant restenosis. Additionally, managing material hydrophobicity by blending synthetic polymers limits adverse effects on bulk properties and controls active substance release. However, the influence of hydrophilic synthetic polymer on human cells in the Cardiovascular system remains to be determined. In this report, effects of both poly(e-caprolactone) (PCL) fibers hydrophilization with Pluronic P123 (P123) and cilostazol (CIL) loading were studied. Physicochemical and mechanical properties of electrospun tubular structures produced from PCL and PCL/P123 fibers with and without CIL were investigated and compared. Release profiles studies and in vitro cell proliferation assays of electrospun materials were conducted. It was found that P123 located near the surface of electrospun fibers increased the rate of CIL release. PCL formulation sustained human umbilical vein endothelial cells (HUVEC) growth for 48 h. Despite improved hydrophilicity, PCL/P123 formulations were found to reduce HUVEC viability. Both PCL and PCL/P123 materials reduced primary aortic smooth muscle cells (PASM) viability after 48 h. In PCL formulations containing CIL, drug release caused a decrease in PASM viability. P123 blending with PCL was found to be as a useful pre-fabrication technique for modulating surface hydrophobicity of electrospun materials and the release profile of incorporated active substance. The cytotoxicity of P123 was evaluated to improve the design of drug-loaded vascular grafts for Cardiovascular Applications.

  • Cilostazol-Loaded Poly(ε-Caprolactone) Electrospun Drug Delivery System for Cardiovascular Applications
    Pharmaceutical Research, 2018
    Co-Authors: Marek Rychter, Bartłomiej Milanowski, Marcin Jarek, Barbara M. Maciejewska, Anna Baranowska-korczyc, Janina Lulek
    Abstract:

    Purpose The study discusses the value of electrospun cilostazol-loaded (CIL) polymer structures for potential vascular implant Applications. Methods Biodegradable polycaprolactone (PCL) fibers were produced by electrospinning on a rotating drum collector. Three different concentrations of CIL: 6.25%, 12.50% and 18.75% based on the amount of polymer, were incorporated into the fibers. The fibers were characterized by their size, shape and orientation. Materials characterization was carried out by Fourier Transformed Infrared spectroscopy (FTIR), Raman spectroscopy, differential scanning calorimetry (DSC) and X-ray diffraction (XRD). In vitro drug release study was conducted using flow-through cell apparatus (USP 4). Results Three-dimensional structures characterized by fibers diameter ranging from 0.81 to 2.48 μm were in the range required for Cardiovascular Application. DSC and XRD confirmed the presence of CIL in the electrospun fibers. FTIR and Raman spectra confirmed CIL polymorphic form. Elastic modulus values for PCL and the CIL-loaded PCL fibers were in the range from 0.6 to 1.1 GPa. The in vitro release studies were conducted and revealed drug dissolution in combination with diffusion and polymer relaxation as mechanisms for CIL release from the polymer matrix. Conclusions The release profile of CIL and nanomechanical properties of all formulations of PCL fibers demonstrate that the cilostazol loaded PCL fibers are an efficient delivery system for vascular implant Application.

Bei Qian - One of the best experts on this subject based on the ideXlab platform.

  • Ultrasound and Magnetic Responsive Drug Delivery Systems for Cardiovascular Application.
    Journal of cardiovascular pharmacology, 2020
    Co-Authors: Bei Qian, Qiang Zhao
    Abstract:

    With the increasing insight into molecular mechanisms of Cardiovascular disease, a promising solution involves directly delivering genes, cells, and chemicals to the infarcted myocardium or impaired endothelium. However, the limited delivery efficiency after administration fails to reach the therapeutic dose and the adverse off-target effect even causes serious safety concerns. Controlled drug release via external stimuli seems to be a promising method to overcome the drawbacks of conventional drug delivery systems (DDSs). Microbubbles and magnetic nanoparticles responding to ultrasound and magnetic fields respectively have been developed as an important component of novel DDSs. In particular, several attempts have also been made for the design and fabrication of dual-responsive DDS. This review presents the recent advances in the ultrasound and magnetic fields responsive DDSs in Cardiovascular Application, followed by their current problems and future reformation.

Bartłomiej Milanowski - One of the best experts on this subject based on the ideXlab platform.

  • Cilostazol-loaded electrospun three-dimensional systems for potential Cardiovascular Application: Effect of fibers hydrophilization on drug release, and cytocompatibility
    Journal of colloid and interface science, 2018
    Co-Authors: Marek Rychter, Bartłomiej Milanowski, Marcin Jarek, Anna Baranowska-korczyc, Bartosz F. Grześkowiak, Mateusz Kempiński, Emerson Coy, Sławomir Borysiak, Janina Lulek
    Abstract:

    Abstract Currently marketed drug-eluting stents are non-selective in their anti-restenotic action. New active substance introduction to polymeric stents and vascular grafts can promote early re-endothelialization, crucial in preventing implant restenosis. Additionally, managing material hydrophobicity by blending synthetic polymers limits adverse effects on bulk properties and controls active substance release. However, the influence of hydrophilic synthetic polymer on human cells in the Cardiovascular system remains to be determined. In this report, effects of both poly(e-caprolactone) (PCL) fibers hydrophilization with Pluronic P123 (P123) and cilostazol (CIL) loading were studied. Physicochemical and mechanical properties of electrospun tubular structures produced from PCL and PCL/P123 fibers with and without CIL were investigated and compared. Release profiles studies and in vitro cell proliferation assays of electrospun materials were conducted. It was found that P123 located near the surface of electrospun fibers increased the rate of CIL release. PCL formulation sustained human umbilical vein endothelial cells (HUVEC) growth for 48 h. Despite improved hydrophilicity, PCL/P123 formulations were found to reduce HUVEC viability. Both PCL and PCL/P123 materials reduced primary aortic smooth muscle cells (PASM) viability after 48 h. In PCL formulations containing CIL, drug release caused a decrease in PASM viability. P123 blending with PCL was found to be as a useful pre-fabrication technique for modulating surface hydrophobicity of electrospun materials and the release profile of incorporated active substance. The cytotoxicity of P123 was evaluated to improve the design of drug-loaded vascular grafts for Cardiovascular Applications.

  • Cilostazol-Loaded Poly(ε-Caprolactone) Electrospun Drug Delivery System for Cardiovascular Applications
    Pharmaceutical Research, 2018
    Co-Authors: Marek Rychter, Bartłomiej Milanowski, Marcin Jarek, Barbara M. Maciejewska, Anna Baranowska-korczyc, Janina Lulek
    Abstract:

    Purpose The study discusses the value of electrospun cilostazol-loaded (CIL) polymer structures for potential vascular implant Applications. Methods Biodegradable polycaprolactone (PCL) fibers were produced by electrospinning on a rotating drum collector. Three different concentrations of CIL: 6.25%, 12.50% and 18.75% based on the amount of polymer, were incorporated into the fibers. The fibers were characterized by their size, shape and orientation. Materials characterization was carried out by Fourier Transformed Infrared spectroscopy (FTIR), Raman spectroscopy, differential scanning calorimetry (DSC) and X-ray diffraction (XRD). In vitro drug release study was conducted using flow-through cell apparatus (USP 4). Results Three-dimensional structures characterized by fibers diameter ranging from 0.81 to 2.48 μm were in the range required for Cardiovascular Application. DSC and XRD confirmed the presence of CIL in the electrospun fibers. FTIR and Raman spectra confirmed CIL polymorphic form. Elastic modulus values for PCL and the CIL-loaded PCL fibers were in the range from 0.6 to 1.1 GPa. The in vitro release studies were conducted and revealed drug dissolution in combination with diffusion and polymer relaxation as mechanisms for CIL release from the polymer matrix. Conclusions The release profile of CIL and nanomechanical properties of all formulations of PCL fibers demonstrate that the cilostazol loaded PCL fibers are an efficient delivery system for vascular implant Application.